共 40 条
Nonphosphorylatable PEA15 mutant inhibits epithelial-mesenchymal transition in triple-negative breast cancer partly through the regulation of IL-8 expression
被引:7
作者:
Park, Jihyun
[1
]
Tacam, Moises J.
[1
]
Chauhan, Gaurav
[1
]
Cohen, Evan N.
[2
]
Gagliardi, Maria
[1
]
Iles, Lakesla R.
[4
]
Ueno, Naoto T.
[1
]
Battula, Venkata L.
[1
,3
]
Sohn, Yoo-Kyoung
[5
]
Wang, Xiaoping
[1
]
Kim, Hak-Sung
[5
]
Krishnamurthy, Savitri
[6
]
Fowlkes, Natalie W.
[7
]
Green, Morgan M.
[7
]
Bartholomeusz, Geoffrey A.
[4
]
Tripathy, Debu
[8
]
Reuben, James M.
[2
]
Bartholomeusz, Chandra
[1
]
机构:
[1] Univ Texas MD Anderson Canc Ctr, Sect Translat Breast Canc Res, Dept Breast Med Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA
[5] Korea Adv Inst Sci & Technol, Dept Biol Sci, Daejeon, South Korea
[6] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA
基金:
美国国家卫生研究院;
关键词:
PEA15;
EMT;
Triple-negative breast cancer;
IL-8;
Ets-1;
DEATH EFFECTOR DOMAIN;
PROTEIN PEA-15;
CELLS;
PROLIFERATION;
INTERLEUKIN-8;
MIGRATION;
BINDING;
PHOSPHORYLATION;
SEQUESTRATION;
METASTASIS;
D O I:
10.1007/s10549-021-06316-2
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Background Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype that lacks targeted therapies. Patients with TNBC have a very poor prognosis because the disease often metastasizes. New treatment approaches addressing drivers of metastasis and tumor growth are crucial to improving patient outcomes. Developing targeted gene therapy is thus a high priority for TNBC patients. PEA15 (phosphoprotein enriched in astrocytes, 15 kDa) is known to bind to ERK, preventing ERK from being translocated to the nucleus and hence blocking its activity. The biological function of PEA15 is tightly regulated by its phosphorylation at Ser104 and Ser116. However, the function and impact of phosphorylation status of PEA15 in the regulation of TNBC metastasis and in epithelial-to-mesenchymal transition (EMT) are not well understood. Methods We established stable cell lines overexpressing nonphosphorylatable (PEA15-AA) and phospho-mimetic (PEA15-DD) mutants. To dissect specific cellular mechanisms regulated by PEA15 phosphorylation status, we performed RT-PCR immune and metastasis arrays. In vivo mouse models were used to determine the effects of PEA15 phosphorylation on tumor growth and metastasis. Results We found that the nonphosphorylatable mutant PEA15-AA prevented formation of mammospheres and expression of EMT markers in vitro and decreased tumor growth and lung metastasis in in vivo experiments when compared to control, PEA15-WT and phosphomimetic PEA15-DD. However, phosphomimetic mutant PEA15-DD promoted migration, mesenchymal marker expression, tumorigenesis, and lung metastasis in the mouse model. PEA15-AA-mediated inhibition of breast cancer cell migratory capacity and tumorigenesis was the partial result of decreased expression of interleukin-8 (IL-8). Further, we identified that expression of IL-8 was possibly mediated through one of the ERK downstream molecules, Ets-1. Conclusions Our results show that PEA15 phosphorylation status serves as an important regulator for PEA15's dual role as an oncogene or tumor suppressor and support the potential of PEA15-AA as a therapeutic strategy for treatment of TNBC.
引用
收藏
页码:333 / 345
页数:13
相关论文